Companies / Materials
NEM
Newmont
Gold
GoldAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health97
Growth94
Profitability100
Cash generation92
Balance sheet100
Dilution control100
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)15.2%Revenue growth (FY)21.3%Revenue CAGR (3y)23.9%Gross margin—Operating margin—Net margin31.3%Free cash flow margin32.2%R&D / revenue0.7%Stock comp / revenue0.4%Net debt / operating cash flow-0.25xCurrent ratio2.29Diluted share count change-3.5%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $12.2B | $11.9B | $11.8B | $18.7B | $22.7B |
| Net income | $1.2B | -$429M | -$2.5B | $3.3B | $7.1B |
| Operating cash flow | $4.3B | $3.2B | $2.8B | $6.4B | $10.3B |
| Capital expenditure | $1.7B | $2.1B | $2.7B | $3.4B | $3.0B |
| Free cash flow | $2.6B | $1.1B | $97M | $3.0B | $7.3B |
| R&D | $154M | $229M | $200M | $197M | $166M |
| Stock-based comp | $72M | $76M | $80M | $89M | $99M |
| Buybacks | $525M | $0 | $0 | $1.2B | $2.3B |
| Dividends | $1.8B | $1.7B | $1.4B | $1.1B | $1.1B |
| Cash | $5.0B | $2.9B | $3.0B | $3.6B | $7.6B |
| Total debt | $5.8B | $5.6B | $10.8B | $9.4B | $5.1B |
| Equity | $22.0B | $19.4B | $29.0B | $29.9B | $33.9B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.